0.5 ml dose of 1.1 mcg VAX-24

Phase 2

Phase 2

Development Phase

Upcoming Catalysts

Historical Events

Regulatory Approvals

No catalyst events have been recorded for this drug yet.

Competitive Landscape

5 competitors in Pneumococcal Vaccines

Drug Information

Target Indication

Pneumococcal Vaccines

Clinical Trial

Last updated: 12/4/2025

Patent & Exclusivity

No patent data available. Pre-approval drugs may not have Orange Book listings.

Drug Science

Mechanism of action & safety profile

Developer

PCVX

Vaxcyte, Inc.

Related Pipeline

Pneumococcal Vaccines

Pneumococcal Vaccines

Pneumococcal Vaccines

Pneumococcal Vaccines

Pneumococcal Vaccines